CORMEDIX INC.

Lobbying for CORMEDIX INC. · Biopharmaceutical company.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Feb 5, 2026

Expenses

$150,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 2172
Preserving Patient Access to Home Infusion Act
S 1058
Preserving Patient Access to Home Infusion Act
HR 6214
Kidney Care Access Protection Act
S 2730
Kidney Care Access Protection Act

Lobbying activity 1

Health Issues

H.R. 2172/S. 1058, Preserving Patient Access to Home Infusion Act H.R. 6214/S. 2730, Kidney Care Access Protection Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.